Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Details)

v3.5.0.2
Fair Value Measurements (Details) - USD ($)
3 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Aug. 31, 2014
2019 convertible senior notes      
Liabilities:      
Principal amount outstanding $ 245,000,000 $ 245,000,000  
2019 convertible senior notes | Senior Notes      
Liabilities:      
Estimated fair value of debt 373,500,000    
Principal amount outstanding     $ 245,000,000.0
Recurring      
Assets:      
Assets, fair value 91,991,000 100,572,000  
Liabilities:      
Liabilities, fair value 9,841,000 14,241,000  
Recurring | Current contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 5,285,000 7,812,000  
Recurring | Current contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value   2,602,000  
Recurring | Long-term contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value 2,444,000 1,355,000  
Recurring | Long-term contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 1,578,000 1,678,000  
Recurring | Liability for amounts owed to former licensees      
Liabilities:      
Liabilities, fair value 534,000 794,000  
Recurring | Cash Equivalents      
Assets:      
Assets, fair value 5,316,000 3,015,000  
Recurring | Short-term investments      
Assets:      
Assets, fair value $ 81,908,000 92,775,000  
Recurring | Note receivable Viking Therapeutics, Inc.      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Estimated volatility of common stock 50.00%    
Assets:      
Assets, fair value $ 4,767,000 4,782,000  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Assets:      
Assets, fair value 4,625,000 6,786,000  
Liabilities:      
Liabilities, fair value 534,000 794,000  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value   0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for amounts owed to former licensees      
Liabilities:      
Liabilities, fair value 534,000 794,000  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash Equivalents      
Assets:      
Assets, fair value 0 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments      
Assets:      
Assets, fair value 4,625,000 6,786,000  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Note receivable Viking Therapeutics, Inc.      
Assets:      
Assets, fair value 0 0  
Recurring | Significant Other Observable Inputs (Level 2)      
Assets:      
Assets, fair value 82,599,000 89,004,000  
Liabilities:      
Liabilities, fair value 2,444,000 3,957,000  
Recurring | Significant Other Observable Inputs (Level 2) | Current contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Other Observable Inputs (Level 2) | Current contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value   2,602,000  
Recurring | Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value 2,444,000 1,355,000  
Recurring | Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Other Observable Inputs (Level 2) | Liability for amounts owed to former licensees      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Other Observable Inputs (Level 2) | Cash Equivalents      
Assets:      
Assets, fair value 5,316,000 3,015,000  
Recurring | Significant Other Observable Inputs (Level 2) | Short-term investments      
Assets:      
Assets, fair value 77,283,000 85,989,000  
Recurring | Significant Other Observable Inputs (Level 2) | Note receivable Viking Therapeutics, Inc.      
Assets:      
Assets, fair value 0 0  
Recurring | Significant Unobservable Inputs (Level 3)      
Assets:      
Assets, fair value 4,767,000 4,782,000  
Liabilities:      
Liabilities, fair value 6,863,000 9,490,000  
Recurring | Significant Unobservable Inputs (Level 3) | Current contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 5,285,000 7,812,000  
Recurring | Significant Unobservable Inputs (Level 3) | Current contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value   0  
Recurring | Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 1,578,000 1,678,000  
Recurring | Significant Unobservable Inputs (Level 3) | Liability for amounts owed to former licensees      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Unobservable Inputs (Level 3) | Cash Equivalents      
Assets:      
Assets, fair value 0 0  
Recurring | Significant Unobservable Inputs (Level 3) | Short-term investments      
Assets:      
Assets, fair value 0 0  
Recurring | Significant Unobservable Inputs (Level 3) | Note receivable Viking Therapeutics, Inc.      
Assets:      
Assets, fair value 4,767,000 $ 4,782,000  
Viking Therapeutics, Inc.      
Liabilities:      
Market value of investment in Viking $ 6,800,000